On-Chain Healing
In the complex and ever-evolving realm of medical science, one of the most transformative shifts has been the emergence and integration of genomics in tailoring treatments and therapies, particularly in the domain of malignant cancer. As we stand at this pivotal juncture, the promise held by genomic data is immense. It harbors the potential to reshape the landscape of cancer treatment by offering insights into individual patient biology, thus steering the course of treatment towards more personalized and effective outcomes. This is the dawn of an era where the code of life, our DNA, becomes the touchstone for medical interventions.
Yet, as with all monumental advancements, the true potential of genomic data can only be realized when it's made both globally accessible and affordable. Imagine a world where every corner of the globe, irrespective of economic divides and geographical barriers, has the means to tap into this treasure trove of data. A world where breakthroughs in biomarker discovery aren't just confined to well-equipped labs in developed nations, but are a global endeavor, driven by collective wisdom and shared data.
Enter the concept of Decentralized On-Chain Genomic Data. By leveraging the power and transparency of blockchain technology, genomic data is no longer siloed. Instead, it's stored on a decentralized platform, ensuring its preservation and accessibility for generations to come. The decentralized nature of this approach circumvents the traditional challenges posed by centralized systems, fostering a more inclusive, collaborative, and transparent environment.
Furthermore, this paradigm shift isn't merely about data storage. By hosting genomic data on-chain, we're also streamlining the process of biomarker discovery. This accelerates the pace at which we can identify and understand the markers crucial for malignant cancer treatment, subsequently enhancing the predictive outcomes in personalized tumor therapy.
In essence, this initiative isn't just a technological marvel; it's a beacon of hope for countless patients worldwide. As the challenges in medicine grow increasingly complex, our commitment to harnessing the power of decentralized on-chain genomic data stands unwavering, aiming to place cutting-edge biomarker discoveries and personalized cancer treatments within reach of all.
An Integration of Pathway Logic
The core premise of On-Chain Healing revolves around establishing pathways between a patient's genetic profile and biomarkers stored in a centralized database.
Contributors and Incentives: The databank's growth is facilitated by geneticists, medical professionals, or diagnostic labs contributing to the repository by adding new biomarkers. Their commitment and contribution are incentivized with a monetary reward. Specifically, for every successful pathway created using the biomarkers they've contributed, they are awarded 34% of the designated fee. This compensation is seamlessly facilitated using a smart contract.
Operational Logic:
A patient approaches a medical professional for consultation or diagnostic purposes.
A sample is procured from the patient, and its DNA is sequenced.
The sequenced DNA is then cross-referenced with the deGenom database to discern if it contains sequences indicative of potential ailments or predispositions to certain diseases.
For utilizing the database's resources and information, a fee is levied.
Fee Distribution: The fee accumulated from referencing the database is meticulously distributed in the following manner:
34% is allocated to the doctor/clinic/laboratory responsible for originally uploading the disease-carrying gene to the database.
8% is distributed among the sales team who, acting as medical representatives, introduced the platform to the gene-contributing doctor/clinic/laboratory, thereby fostering an active participation in deGenom.
16% is directed to deGenom's proprietary funds, ensuring the platform's sustainability and growth.
8% is awarded to another set of sales representatives. These representatives are responsible for inviting the doctor/clinic/laboratory/private individual initiating the verification to use the deGenom platform.
The remaining 34% is attributed to the medical professional treating the patient and initiating the genetic cross-referencing.
This comprehensive and strategic fee distribution system not only encourages continuous contribution to the database but also fosters a network of active users, ensuring the platform remains current, widely-used, and at the forefront of genetic diagnostics and treatment pathways.
Last updated